HomeProceduresKidney Transplant

Kidney Transplant

A donor kidney is placed in the iliac fossa with vascular and ureteric anastomoses to treat end-stage kidney disease; the native kidneys are usually left in place.

Surgical Right or left iliac fossa (groin/lower abdomen) Avg. stay 21 days 0 clinics

Overview

Kidney transplantation is the preferred renal replacement therapy for end-stage kidney disease, offering better survival and quality of life than long-term dialysis for suitable candidates. Grafts may come from deceased donors (DBD or DCD) or from a living donor (related, unrelated, or paired/altruistic). Indications include diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritides, polycystic kidney disease and other causes of CKD stage 5. NHS Blood and Transplant describes the operation as a 2-4 hour procedure in which the donor kidney is placed extraperitoneally in the right or left iliac fossa. The renal vein and artery are anastomosed end-to-side to the external iliac vein and artery, and the donor ureter is reimplanted into the bladder, usually over a temporary double-J stent. The native kidneys are typically left in situ, so the recipient ends up with three kidneys. Typical hospital stay is 5-10 days. Pre-emptive transplantation (before dialysis is started) is associated with better outcomes. Lifelong immunosuppression - usually tacrolimus, mycophenolate and a tapering steroid - is required. International patients often need to stay in-country for about three weeks for the immediate post-operative period and the first close monitoring period, with the stent removed at around 6 weeks. One-year graft survival exceeds 95 percent in established centres. Sources: NHS Blood and Transplant, NICE, NIH transplant literature.

Hospital & stay

2–3 nights
Hospital stay
21 days
Total stay abroad
Surgical
Procedure type

Procedure details

How it's performed

Under general anaesthesia, the surgeon makes an oblique lower-abdominal (iliac fossa) incision and dissects extraperitoneally to expose the external iliac artery and vein. The donor kidney is brought to the field on ice. The renal vein is anastomosed end-to-side to the external iliac vein, then the renal artery to the external iliac artery; clamps are released and the kidney reperfused. The donor ureter is implanted into the bladder over a double-J stent. The wound is closed in layers and a closed-suction drain may be placed.

Preparation
  1. 1Comprehensive transplant work-up: tissue typing, virology, cardiac and pulmonary fitness, dental review.
  2. 2Listing on the national transplant registry; or directed/altruistic living-donor work-up.
  3. 3Optimise dialysis and fluid balance; treat any infection or peripheral vascular disease.
  4. 4Vaccinations (hepatitis B, pneumococcus, influenza, varicella) before transplantation.
  5. 5Cross-match and pre-operative bloods; patient education on lifelong immunosuppression and self-monitoring.
Recovery
  1. 1Day 0-1: High-dependency monitoring; urine output and creatinine tracked closely.
  2. 2Days 1-7: Ward-based recovery with daily ultrasound if indicated; immunosuppression initiated and adjusted.
  3. 3Days 5-10: Discharge once graft function is stable, drain removed and patient self-caring.
  4. 4Weeks 2-6: Twice-weekly outpatient bloods initially, decreasing as graft function stabilises.
  5. 5Weeks 6-12: Double-J stent removed at cystoscopy; gradual return to work.
  6. 6Lifelong: Annual review, cancer and infection surveillance, lifelong immunosuppression.

Related procedures

Related procedures

What the research says about kidney transplantation

14 peer-reviewed sources

Kidney transplantation is widely regarded as the treatment of choice for many people with kidney failure, offering survival and quality-of-life advantages over long-term dialysis in suitable candidates. Evidence from registry cohorts, systematic reviews, and clinical practice guidelines informs donor selection, immunosuppression, and the prevention of complications such as rejection, infection, and post-transplant diabetes. Graft and patient survival have improved over time, though outcomes depend on donor type, recipient health, and lifelong adherence to medication and follow-up. Ongoing research addresses older recipients, ABO-incompatible transplantation, organ preservation, and cardiovascular and metabolic risk after surgery. The references below are drawn from peer-reviewed meta-analyses, Cochrane reviews, registry analyses, and guideline-level sources.

  1. The Role of Rituximab in ABO-Compatible Renal Transplantation: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Alotaibi AY et al. · Medicina (Kaunas, Lithuania) · 2026
    Systematic review and meta-analysisPMID 42075508DOI
  2. Kidney transplantation in adult candidates with obesity: Guidelines by the Association Française d'Urologie and Société Francophone de Transplantation.
    Timsit MO et al. · The French journal of urology · 2026
    Clinical guidelinePMID 41912112DOI
  3. Evaluating Infections in Solid Organ Donors Before Transplantation: A Systematic Review of Clinical Practice Guidelines.
    Chong CH et al. · Transplantation · 2026
    Clinical guidelinePMID 41805905DOI
  4. Kidney transplant outcomes in patients aged ≥ 70 years: a systematic review and meta-analysis of multicenter or registry-based studies with future directions and a multicenter study proposal.
    Prevezanos D et al. · International urology and nephrology · 2026
    Systematic review and meta-analysisPMID 42001369DOI
  5. Cardiovascular and Renal Outcomes Among Kidney Transplant Recipients With Metabolic Syndrome: A Systematic Review and Meta-Analysis.
    Lim MY et al. · Clinical transplantation · 2026
    Systematic review and meta-analysisPMID 41915369DOI

Compiled from peer-reviewed medical literature indexed on PubMed. This overview is for general education and is not medical advice. · Last updated 2026-06-15